From research grants, to exciting discoveries and treatment breakthroughs, read the latest research news from the Melanoma Institute Australia team as we work tirelessly towards our goal of zero deaths from melanoma.
MIA team share learnings at two international conferences
Read more about how the MIA team continues to play a leading role in advancing the frontiers of melanoma research, presenting new findings at two major international oncology conferences - the AACR Annual Meeting in San Diego, and the EADO Congress in Prague.
Streamlining assessment of pathological response after neoadjuvant treatment
Neoadjuvant immunotherapy continues to transform outcomes for people with melanoma and other cancers. Two recent papers show that assessing pathological response after neoadjuvant immunotherapy can be both more efficient and more consistent, without compromising accuracy.
Assoc Prof Inês da Silva receives two prestigious awards in one night!
Assoc Prof Inês da Silva, Medical Oncologist & Senior Researcher at MIA, was recently presented with the inaugural 'Marie Krogh Young Women in Science Prize' and the 'NSW Premier’s Awards Outstanding Mid-Career Researcher of the Year', in recognition of her groundbreaking contributions to melanoma treatment and care.
Adjuvant vs Neoadjuvant – Further evidence for pre-surgery immunotherapy
Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
Beyond NADINA – The new wave of neoadjuvant clinical trials
MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
Personalising treatment options for complex lentigo maligna
Researchers have reported results from an international clinical trial assessing alternative treatment options for lentigo maligna - a non-invasive condition that commonly occurs on sun-exposed areas, particularly the face.
Global award for neoadjuvant immunotherapy
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
Public consultation on Melanoma Clinical Guidelines
Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.
Breakthrough melanoma treatment listed on PBS
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
NHMRC grants for UNCUT and Automate Me clinical trials
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
MIA clinicians & researchers share latest results at ASCO25
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
